Machine Learning for prediction of violent behaviors in schizophrenia spectrum disorders: a systematic review
- PMID: 38577400
- PMCID: PMC10991827
- DOI: 10.3389/fpsyt.2024.1384828
Machine Learning for prediction of violent behaviors in schizophrenia spectrum disorders: a systematic review
Abstract
Background: Schizophrenia spectrum disorders (SSD) can be associated with an increased risk of violent behavior (VB), which can harm patients, others, and properties. Prediction of VB could help reduce the SSD burden on patients and healthcare systems. Some recent studies have used machine learning (ML) algorithms to identify SSD patients at risk of VB. In this article, we aimed to review studies that used ML to predict VB in SSD patients and discuss the most successful ML methods and predictors of VB.
Methods: We performed a systematic search in PubMed, Web of Sciences, Embase, and PsycINFO on September 30, 2023, to identify studies on the application of ML in predicting VB in SSD patients.
Results: We included 18 studies with data from 11,733 patients diagnosed with SSD. Different ML models demonstrated mixed performance with an area under the receiver operating characteristic curve of 0.56-0.95 and an accuracy of 50.27-90.67% in predicting violence among SSD patients. Our comparative analysis demonstrated a superior performance for the gradient boosting model, compared to other ML models in predicting VB among SSD patients. Various sociodemographic, clinical, metabolic, and neuroimaging features were associated with VB, with age and olanzapine equivalent dose at the time of discharge being the most frequently identified factors.
Conclusion: ML models demonstrated varied VB prediction performance in SSD patients, with gradient boosting outperforming. Further research is warranted for clinical applications of ML methods in this field.
Keywords: artificial intelligence; machine learning; schizophrenia; schizophrenia spectrum disorder; violent behavior.
Copyright © 2024 Parsaei, Arvin, Taebi, Seyedmirzaei, Cattarinussi, Sambataro, Pigoni, Brambilla and Delvecchio.
Conflict of interest statement
The authors declare the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Offenders and non-offenders with schizophrenia spectrum disorders: the crime-preventive potential of sufficient embedment in the mental healthcare and support system.Front Psychiatry. 2023 Aug 30;14:1231851. doi: 10.3389/fpsyt.2023.1231851. eCollection 2023. Front Psychiatry. 2023. PMID: 37711423 Free PMC article.
-
[Three clinical risk profiles of violent behavior in a cohort of early psychosis patients].Encephale. 2019 Jun;45(3):214-220. doi: 10.1016/j.encep.2018.08.003. Epub 2018 Nov 13. Encephale. 2019. PMID: 30446287 French.
-
Identification of violent patients with schizophrenia using a hybrid machine learning approach at the individual level.Psychiatry Res. 2021 Dec;306:114294. doi: 10.1016/j.psychres.2021.114294. Epub 2021 Nov 17. Psychiatry Res. 2021. PMID: 34823086
-
The use of machine learning on administrative and survey data to predict suicidal thoughts and behaviors: a systematic review.Front Psychiatry. 2024 Mar 4;15:1291362. doi: 10.3389/fpsyt.2024.1291362. eCollection 2024. Front Psychiatry. 2024. PMID: 38501090 Free PMC article.
-
Machine learning techniques in diagnostics and prediction of the clinical features of schizophrenia: a narrative review.Consort Psychiatr. 2023 Sep 29;4(3):43-53. doi: 10.17816/CP11030. Consort Psychiatr. 2023. PMID: 38249535 Free PMC article. Review.
Cited by
-
Construction of a troublemaking risk assessment tool for patients with severe mental disorders in community of China.Sci Rep. 2025 Jan 3;15(1):663. doi: 10.1038/s41598-024-84486-x. Sci Rep. 2025. PMID: 39753785 Free PMC article.
References
-
- Karbalaee M, Jameie M, Amanollahi M, TaghaviZanjani F, Parsaei M, Basti FA, et al. . Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial. Schizophr Res. (2023) 254:92–8. doi: 10.1016/j.schres.2023.02.020 - DOI - PubMed